Takeda releases latest data on phase 3 clinical trials of the quadnage dengue vaccine TAK-003
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Takedacompany(http://released the latest data from its quadrat dengue vaccine, TAK-003, in the key phase 3 clinicaltrial(http://TIDESTHE OVERALL VACCINE EFFICACY (VE) OF TAK-003 IS NOT ONLY BASICALLY CONSISTENT WITH THE PREVIOUS PRIMARY ENDPOINT
ANALYSIS
(HTTP://WWW.CHEMDRUG.COM/SELL/76/)
DATA, BUT ALSO REACHES ALL SECONDARY ENDPOINTS VERIFIED BY SUFFICIENT CASE COUNTSThe TAK-003 developed by Takeda is a quadriceps dengue vaccine, a live vaccine based on the type 2 virusIn Phases 1 and 2 clinical trials, vaccinated adolescents responded to all four dengue viruses and were safe and well toleratedPhase 3 clinical trial called TIDES is a four-and-a-half-year randomized, double-blind, placebo-controlled trial designed to verify the preventive role of TAK-003 in children aged 4 to 16 who have been exposed to and have not been exposed to dengue feverThe experimental data included overall VE update data for 18 months after the second injection of immunity, as well as the results of the evaluation of secondary endpoints by serotype, baseline serum status, and disease severityThe results showed that TAK-003 was able to prevent dengue fever with 73.3% effectiveness, which was broadly in line with the data in the previous major endpoint analysis report (80.2%)In addition, TAK-003 reached all the secondary endpoints of the trial, including 90.4% of THE VE sons and 85.9% of the patients admitted to dengue fever and 85.9% for dengue fever
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
